RGDXQ (Response Genetics) EBIT: $-18.68 Mil (TTM As of Dec. 2015)


What is Response Genetics EBIT?

Response Genetics RGDXQ -98.00% EBIT is $-18.68 Mil as of Dec. 2015.

Response Genetics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2015 was $0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2015 was $-18.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Response Genetics's annualized ROC % for the quarter that ended in Dec. 2015 was 0.00%. Response Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2015 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Response Genetics  (OTCPK:RGDXQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Response Genetics's annualized ROC % for the quarter that ended in Dec. 2015 is calculated as:

ROC % (Q: Dec. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2015 ) + Invested Capital (Q: Dec. 2015 ))/ count )
=0 * ( 1 - 0% )/( (5.796 + 22.972)/ 2 )
=0/14.384
=0.00 %

where

Invested Capital(Q: Mar. 2015 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.778 - 3.247 - ( 1.735 - max(0, 4.877 - 8.756+1.735))
=5.796

Invested Capital(Q: Dec. 2015 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=48.884 - 7.579 - ( 19.459 - max(0, 9.865 - 28.198+19.459))
=22.972

Note: The Operating Income data used here is four times the quarterly (Dec. 2015) data.

2. Joel Greenblatt's definition of Return on Capital:

Response Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2015 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2015 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2015  Q: Dec. 2015
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (1.265 + max(2.249, 0)) + (6.069 + max(0.329, 0)) )/ 2 )
=0/( ( 3.514 + 6.398 )/ 2 )
=0/4.956
=0.00 %

where Working Capital is:

Working Capital(Q: Mar. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.059 + 0 + 0.962) - (3.247 + 0 + 1.525)
=2.249

Working Capital(Q: Dec. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.621 + 0.133 + 1.985) - (7.579 + 0.831 + 1.7763568394003E-15)
=0.329

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2015) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Response Genetics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2015 )
=-18.681/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics EBIT Related Terms

Response Genetics EBIT Historical Data

* Premium members only.

The historical data trend for Response Genetics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics EBIT Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.68 -7.67 -10.65 -18.52 -21.02

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 -3.39 -8.54 -3.64 0.00

RGDXQ vs PSID, GBSN, ETAH: EBIT Comparison

For the Diagnostics & Research subindustry, Response Genetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Response Genetics's EV-to-EBIT falls into.


Response Genetics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-18.68 Mil mean?
Response Genetics (RGDXQ) has a EBIT of $-18.68 Mil as of Dec. 2015. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Response Genetics.
Is Response Genetics' EBIT too high?
Response Genetics' current EBIT is $-18.68 Mil.
How does Response Genetics' EBIT compare to PSID and GBSN?
Response Genetics' EBIT of $-18.68 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Response Genetics. Response Genetics's current EBIT is $-18.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current EBIT of $-18.68 Mil. The current EBIT is $-18.68 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current EBIT is $-18.68 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.